Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.44 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.44 |
| ▸ | RAF1 | P04049 | 1/20 | 0.34 |
| ▸ | CASP3 | P42574 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.30 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23055886 | 0.89 | NR1H2 (0.45) | NR1H2NR1H3RAF1CASP3MAPT | |
| SCHEMBL23055854 | 0.85 | NR1H2 (0.32) | NR1H2NR1H3RAF1MAPTATAD2 | |
| SCHEMBL23055766 | 0.84 | ALDH1A1 (0.44) | CASP3MAPTGAAMEN1ALDH1A1 | |
| SCHEMBL23055657 | 0.82 | MAPT (0.49) | MAPTSMN1; SMN2MEN1ALDH1A1HPGD | |
| SCHEMBL23055608 | 0.82 | CASP1 (0.52) | NR1H2NR1H3CASP3MAPTGAA | |
| SCHEMBL23055866 | 0.82 | CRBN (0.34) | MAPTGAASMN1; SMN2ALDH1A1DDB1 | |
| SCHEMBL23055396 | 0.75 | NR1H2 (0.33) | NR1H2NR1H3 | |
| SCHEMBL23055997 | 0.74 | NR1H2 (0.33) | NR1H2NR1H3 | |
| SCHEMBL23055547 | 0.73 | ALDH1A1 (0.45) | CASP3MAPTMEN1ALDH1A1HPGD | |
| SCHEMBL23055646 | 0.73 | CRBN (0.34) | MAPTGAASMN1; SMN2ALDH1A1DDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11795147-B2 | Modulators of complex I | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-10-24 | — | — | US | disclosed |
| US-11795147-B2 | Modulators of complex I | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-10-24 | — | — | US | disclosed |
| US-20210061761-A1 | MODULATORS OF COMPLEX I | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210061761-A1 | MODULATORS OF COMPLEX I | NDUFAB1, NDUFV1, NDUFB7 | NR1H2 385/4885NR1H3 685/4885RAF1 3338/4885 |
| US-11795147-B2 | Modulators of complex I | NDUFAB1, NDUFV1, NDUFB7 | NR1H2 385/4885NR1H3 685/4885RAF1 3338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.